Paltusotine can alleviate symptoms of carcinoid syndrome in patients with neuroendocrine tumors, a phase 2 study suggests.
NP-101 plus nivolumab and ipilimumab demonstrated activity in patients with metastatic EP-NECs that were refractory to chemotherapy.
The combination of chemotherapy and radioembolization appeared safe and effective in patients with well-differentiated, liver-dominant, grade 3 NETs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback